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ABSTRACT
Embedding microfluidic architectures with microneedles enables fluid management capabilities that present new degrees of freedom for
transdermal drug delivery. To this end, fabrication schemes that can simultaneously create and integrate complex millimeter/centimeter-
long microfluidic structures and micrometer-scale microneedle features are necessary. Accordingly, three-dimensional (3D) printing tech-
niques are suitable candidates because they allow the rapid realization of customizable yet intricate microfluidic and microneedle features.
However, previously reported 3D-printing approaches utilized costly instrumentation that lacked the desired versatility to print both features
in a single step and the throughput to render components within distinct length-scales. Here, for the first time in literature, we devise a fab-
rication scheme to create hollow microneedles interfaced with microfluidic structures in a single step. Our method utilizes stereolithography
3D-printing and pushes its boundaries (achieving print resolutions below the full width half maximum laser spot size resolution) to create
complex architectures with lower cost and higher print speed and throughput than previously reported methods. To demonstrate a potential
application, a microfluidic-enabled microneedle architecture was printed to render hydrodynamic mixing and transdermal drug delivery
within a single device. The presented architectures can be adopted in future biomedical devices to facilitate new modes of operations for
transdermal drug delivery applications such as combinational therapy for preclinical testing of biologic treatments.
© 2019 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license
(http://creativecommons.org/licenses/by/4.0/). https://doi.org/10.1063/1.5127778
INTRODUCTION
Advancements in bioengineering and materials science have
accelerated the progression toward personalized medicine by creat-
ing technologies that facilitate disease diagnosis and delivery of care
at the “point-of-person.”1–3 Among the many technologies critical
to the realization of personalized medicine, transdermal drug
delivery is one of the most important, because it enables safe, pain-
less, and convenient drug delivery.4 In this regard, microneedles
provide promising solutions for transdermal drug delivery because
of their minimally invasive nature. Microneedles were previously
constructed with a wide variety of materials including metals,
ceramics, and polymers.5–7 Among these materials, biocompatible
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polymer microneedles have undergone widespread adoption over
metal or ceramic microneedles due to their ability to be manufac-
tured at low costs, safely disposed after use, and tailored for
customized drug release needle profiles.8
The diversity and versatility of operations enabled by micro-
needles can be augmented through the integration of microfluidic
devices to achieve new drug delivery capabilities.9–11 Specifically,
the ability of microfluidics to rapidly transport and mix small
volumes of fluids, while varying reaction conditions (e.g., flow rates
and reactant concentrations) to optimize the resulting products,
makes it an effective technology to deliver numerous operations rel-
evant to transdermal drug delivery.12 For example, microfluidic
mixing was used to directly synthesize nanoparticles with tunable
physicochemical properties such as particle size, homogeneity, and
drug loading and release at the point of delivery.13 Additionally,
the combination of microneedles and microfluidic mixing is benefi-
cial in areas such as combinational therapy-based subcutaneous/
transdermal administration for preclinical testing of biologic treat-
ments.14 As more treatments are developed for codosing, where
patients receive multiple treatments simultaneously, the availability
of subcutaneous/transdermal alternatives could reduce treatment
complexity and costs, allowing flexibility in combining different
biologics without extensive formulation development.14
Conventional fabrication schemes are not well-suited to realize
both microneedles and microfluidic structures within a single device,
because they cannot efficiently and/or simultaneously realize features
that operate at two distinct length-scale domains. Operationally, epi-
dermal penetration for enhanced drug permeability requires
micrometer-scale microneedles,15 while microfluidic channels route
and manipulate microliters of fluid within millimeter/centimeter-long
devices.16 As a result, previous work commonly relied on the fabrica-
tion of microneedles and microfluidic channels as disjointed
modules, which were individually constructed via separate, costly, and
multistep techniques.23 For instance, microneedle fabrication pro-
cesses consist of micromolding, electrodeposition, mold-based
etching, and/or solvent casting,19–22 while microfluidic channel fabri-
cation processes include laser-cutting, micromilling, and/or lithogra-
phy.17,18 Therefore, a suitable alternative is preferred, which is capable
of rendering both types of structures with both the required resolu-
tion for epidermal penetration and higher-throughput manufacturing.
Accordingly, 3D-printing is a suitable alternative to conven-
tional fabrication methods because, in principle, it allows the
realization of customizable and intricate microfluidic/microneedle
architectures without the commonly required investments.23
However, previously reported 3D-printed microchannel-microneedle
platforms relied on expensive two-photon polymerization (2PP)
3D-printers to print microneedles and required additional processes
to integrate with separately fabricated microchannels.24 While 2PP
offers high print resolutions down to the 200 nm regime, studies
have shown that microneedle tips with ∼30 μm radius of curvature
are enough for epidermal penetration.25 Furthermore, the small
build volume (8mm maximum object height) and long print times
(e.g., ∼3 h for a 1 × 1 × 6mm3 spring) associated with 2PP machines
make the technology impractical for rendering larger features such
as millimeter/centimeter-long microfluidic channels.26
Here, we present a rapid, low-cost, and single-step stereoli-
thography (SLA)-based 3D-printing scheme to simultaneously
render multiscale features (from micrometers to centimeters) and
unify them into microfluidic-enabled microneedle devices. SLA
printers offer the ability to simultaneously and efficiently print sub-
millimeter/centimeter-scale components with larger build volumes
(∼20–30 cm maximum height), shorter print times (e.g., ∼15 min
for the equivalent 6 mm tall spring26), and substantially higher
throughput than 2PP printers without any compromise in device
performance. These operational advantages, combined with the
lower cost and weight of commercially available SLA printers,27,28
make them viable for field deployment in lower resource settings,
where transdermal drug delivery devices can be rapidly prototyped
and tailored toward an individual patient’s needs.
To harvest the benefits of SLA-based fabrication schemes for
envisioned applications, the limitations of standard SLA printers
must be overcome to reach the resolutions required for optimal
microneedle performance (e.g., in terms of ease of penetration and
minimized pain). In this regard, we devised an elaborate hollow
microneedle design and a refined print setup to produce needle
tips substantially finer than the SLA printer’s laser spot size and
with high yield. To demonstrate the utility of the presented microfl-
uidic/microneedle fabrication approach, we 3D-printed an architec-
ture consisting of a hydrodynamic mixing module interfaced with a
hollow microneedle array. This architecture allows the modulation
of the input fluid solutions’ flow rates to facilitate programmable
drug delivery in future combinational therapy-based applications.
MATERIALS AND METHODS
Microchannel-microneedle fabrication and design
The microfluidic-enabled microneedle device was fabricated
using an SLA printer (Formlabs, Form 2) and class IIa biocompati-
ble resin (Formlabs, Dental LT Clear). The resin is a mixture of
methacrylic acid esters and photoinitiator comprised of (in % w/w)
>70% methacrylic oligomer, <20% glycol methacrylate, <5%
pentamethyl-piperidyl sebacate (EG No. 255-437-1), and <5%
phosphine oxide (EG No. 278-355-8).50 It possesses high optical
transparency for visual characterization and flexural strength
greater than 50MPa and supports a print resolution of 100 μm.
The device was designed in computer-aided design (CAD) software
(Autodesk, Fusion 360) and preprocessed in 3D-printer preparation
software (Formlabs, PreForm). Within PreForm, 0.6 mm touch
point sizes were automatically generated at the default support
density. Supports were adjusted to ensure they were not arranged
near critical features such as the microchannel inlets and hollow
microneedles (4 × 4 array). To optimize microneedle yield and
quality, the model was oriented at 45° to the build platform.
Following SLA printing, the printed parts were washed in isopropyl
alcohol (IPA, 99.9% v/v) for 5 min (Formlabs, FormWash) and
cured in a 405 nm wavelength UV chamber at 80 °C for 20min
(Formlabs, FormCure) to maximize stiffness and strength.
Microneedle penetration and mechanical
characterization
Penetration tests were performed with parafilm (8 layers,
∼1.1 mm total thickness) and a 500 g weight (∼5 N). The micro-
needles were placed on top of the parafilm, onto which the weight
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was applied for 1 min. The microneedles were then removed and
the parafilm unfolded to examine the depth of penetration.
Microneedle fracture tests were conducted on the syringe-shaped
microneedle arrays using an Instron 5943. Arrays were placed
needle-side up on the stage and compressed with a 10 kN load cell
at 1 mm/min up to 50 N of applied force. After five independent
trials, the mean forces and standard deviations (±SDs) were calcu-
lated. 0.4% wt/vol trypan blue in phosphate-buffered saline (PBS;
Sigma Aldrich) was used for porcine skin (Stellen Medical, 1.5 mm
thick) penetration testing to stain the perforation sites.
For mechanical simulation (Autodesk, Fusion 360), a 0.05 N
force was applied to a single needle tip to emulate the force per
needle applied from the penetration tests. The cylindrical extrusion
at the tip of the needle was replaced with a half-sphere to replicate
the final printed structure.
Microfluidic characterization
Microfluidic tests were performed with dye solutions (Adam’s
Extract) and programmable syringe pumps (Harvard Apparatus,
Pump 11 Pico Plus and PHD ULTRA). The syringes were pumped
at four flow rate ratios (1:1:1, 0.1:0.1:1, 0.1:1:0.1, and 1:0.1:0.1) cor-
responding to the flow rates of the red-dyed, clear water, and blue-
dyed solutions (Q1:Q2:Q3). To visualize hydrodynamic mixing
characteristics, the following flow rates were applied. For the 1:1:1
baseline flow rate, 100 μl/min was applied to all three inlets. For the
0.1:0.1:1, 0.1:1:0.1, and 1:0.1:0.1 flow rates, 10 μl/min and 100 μl/min
were used for 1 and 10 flow rate ratios, respectively.
Three fluorochrome-water solutions were used for concentra-
tion measurements: rhodamine B, fluorescein isothiocyanate, and
methylene blue (Sigma Aldrich) at 0.5% wt/vol concentrations.
Fluorescent dye concentrations were measured with 25 μl sample
volume in a 384-well microplate (Thermo Fisher Scientific) and a
microplate reader (Tecan, Infinite M1000 Pro). Excitation wave-
lengths of 545 nm, 489 nm, and 664 nm, and emission wavelengths
of 566 nm, 517 nm, and 690 nm were used for rhodamine B, fluor-
escein isothiocyanate, and methylene blue, respectively.
Porcine skin fluorochrome delivery and image analysis
Porcine skin was cut into 2 × 2 cm pieces and the same
fluorochrome-water solutions used for microfluidic characterization
were used for model-drug delivery tests. The combined spiral
microfluidic and microneedle device was pressed onto the porcine
skin, and the fluorochrome solutions were injected with the aid of
the syringe pumps. Identical instrumentation and flow rate ratios
from the microfluidic characterization were used in these tests
(where the absolute flow rates were reduced by a factor of 10 to
minimize leakage).
After removing the device, images of the porcine skin penetra-
tion area were captured using confocal microscopy (Figs. S5–S8 in
the supplementary material), and the raw fluorescence intensities
of all images were quantified using ImageJ software. This process
was repeated for each fluorochrome to obtain their intensities at
various skin depths. The integral of the interpolated intensity vs
the skin depth curve (yielding total intensity) for each fluoro-
chrome is used to infer the dye amount delivered to the skin. Then,
these values were divided by their respective total intensities
captured at the 1:1:1 baseline flow rate condition for ease of
comparison.
Scanning electron and confocal laser scanning
microscopy
The microneedles and microchannels were imaged using scan-
ning electron microscopy (Hitachi S4700 SEM) with an accelerating
voltage of 10 kV. All samples were sputtered with a 7 nm gold
coating prior to imaging (Anatech Ltd, Hummer 6.2).
Fluorescence images of each fluorochrome were taken using a
confocal laser scanning microscope (Leica, TCS-SP5). For rhoda-
mine B, a 543 nm wavelength HeNe laser was set at 80% intensity
and fluorescence between 560 and 640 nm wavelengths were cap-
tured. For fluorescein isothiocyanate, 496 and 488 nm wavelength
argon lasers were both set at 100% and fluorescence between 510
and 560 nm wavelengths were captured. Lastly, for methylene blue,
a 633 nm HeNe laser was set at 25% intensity and fluorescence
between 650 and 750 nm wavelengths were captured. Smart gain
was 700 across all samples, and five images were taken at 100 nm
steps across 0–400 μm skin depths (0 μm represents the skin
surface).
RESULTS AND DISCUSSION
Microneedle fabrication with SLA 3D-printing
As conceptualized in Fig. 1(a), we leveraged SLA 3D-printing
to fabricate a single-piece, multi-inlet, 3D microfluidic device with
an embedded hollow microneedle array. The utilized printer directs
UV light through an optical window below the build platform and
additively manufactures the designed model by curing a photopoly-
mer resin layer-by-layer within the resin tank. Figure 1(b) show-
cases a representative postprinted device and highlights its core
microfluidic and microneedle components: an illustrative 3D
hydrodynamic mixing microfluidic module and a syringe-shaped
microneedle array. Final device dimensions are 1.5 × 1.2 × 3.1 cm3,
and 12 devices can be created in 2.5 h in a single print (effectively
yielding 12.5 min per device). Furthermore, the material selected
for device fabrication (Formlabs, Dental LT Clear) is a class IIa bio-
compatible resin, which belongs to a category of materials previ-
ously shown to be suitable for transdermal applications.29,33
Investigation and optimization of microneedle design
To optimize for penetration performance, we investigated
various microneedle geometries while following previously estab-
lished design guidelines, which require the width, bore, and length
of the microneedles to be approximately 1 mm.30,31 In accordance
with previous studies, we also minimized the radius of curvature of
the needle tips to reduce pain and insertion force, thereby promot-
ing ease of penetration for the average patient.30
To determine the optimal print setup, we printed a basic
sheared-cylinder microneedle design (900 μm tall cylinder with a
45° cut) at different orientations (0°, −45°, +45°, and 90° to the
print bed). Optical images of microneedles printed at these orienta-
tions are found in Figs. 2(a)–2(d) (with outlined profiles) and
Fig. S1 in the supplementary material (without outlined profiles).
We found that +45° led to the highest microneedle quality, as this
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orientation allowed the resin flow (caused by build platform move-
ment) to exert less transverse forces on the tip of the needles, thus
mitigating structural warpage. Although the 0° orientation did not
cause significant microneedle warpage, it required more complex
support structures and resulted in less successful prints.
After determining the ideal print angle, we printed hollow
microneedles with different geometries (all with the +45° angle) to
ascertain the most effective overall design. Each geometry was
designed with an 800 μm wide base, 600 μm center bore, and
heights below 1 mm. These hollow microneedle interfaces enable
transdermal drug delivery through a “poke-and-flow” mode of
operation,32 where the tip creates micropores in the skin, followed
by the delivery of fluids flowing through the hollow microneedle
bore. The printed geometries included two of the most commonly
reported 3D-printed microneedle designs: a pyramidal microneedle
with a triangular base and tip orthogonally aligned with a vertex of
the base,33,34 and a conical microneedle with tapered sidewalls.35–37
In Figs. 2(e) and 2(f ), scanning electron microscope (SEM) images
of the pyramidal and conical microneedles in 10 × 10 arrays are
shown, respectively. Additionally, we devised a third “syringe-
shaped” design that adopted an oblique cone structure with
sharper tips than the previous designs [Fig. 2(g)]. To assess the
consistency of the SLA-printed features, for each array, we charac-
terized and compared the microneedle heights. Figure 2(h) shows
that the average height of the conical, pyramidal, and syringe-
shaped microneedles was 900 μm, 730 μm, and 710 μm, respectively
(error bars indicate ±standard deviation). The small standard devi-
ations (∼10 μm) across all three designs indicate that the devised
SLA printing approach is capable of printing large microneedle
arrays of the same design with high degrees of consistency.
To achieve ease of penetration, the radius of curvature at the
needle tip must be further minimized, well below the SLA printer’s
full width half maximum (FWHM) laser spot size (140 μm).40
Accordingly, as shown in Figs. 2(i) and 2( j), we incorporated auxil-
iary design features to further enhance the tip sharpness.
Specifically, we added a cylindrical element (diameter: 40 μm,
height: 80 μm) to the tip to enforce a high height-to-base aspect
ratio, which decreases the effect of diffraction leading to “false
printing.”25 The false printing phenomenon is illustrated in
Fig. S10(a) in the supplementary material, where the expected print
resolution is the FWHM spot size, but the diffracted light can cure
the photopolymer in undesired areas around the spot size. With a
low aspect ratio design [Fig. S10(b) in the supplementary material],
there is more exposed material around the laser spot, causing unde-
sired curing that propagates through the subsequent layers due to
the gradual transition from a large to small cross-sectional area.
With a high aspect ratio tip, which eliminates the cross-sectional
area transition entirely [Fig. S10(c) in the supplementary material],
FIG. 1. 3D-printing of microfluidic-enabled hollow microneedle devices. (a) CAD model of a representative microfluidic-enabled microneedle device as an input to the SLA
printer. (b) The printed device with three microfluidic inlets converging into a 3D spiral chamber and to a hollow microneedle array outlet. (c) Close-up of the inlet junction
visualizing the convergence of red-dyed, clear, and blue-dyed solution streams. (d) Close-up of the hollow microneedle array.
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the final layers are constructed through the vertical stacking of
single-point layers, thus reducing the effects of excess material
forming around the spot size and allowing the tip to achieve a
smaller overall cross-sectional area. By adding this cylindrical
element, we rendered fine-tip syringe-shaped microneedles with
radii of curvature as low as 25 μm.
To achieve a 100% hole formation success rate without the
need for further postprocessing fabrication steps, we added a fillet
to the perimeter of the microneedle’s bore to increase its opening.
As shown in Fig. S11(a) in the supplementary material, without the
fillet, we achieved approximately 50% hole formation. After adding
the fillet, 100% hole formation rate was obtained [Fig. S11(b) in the
supplementary material]. This fillet is shown in Fig. 2( j) as the
blue feature along the edge of the microneedle bore, which resem-
bles a blue ring. Figure 2(k) shows an SEM image of the final
fine-tip microneedle in a 10 × 10 array. We repeated the needle-
FIG. 2. Characterization of 3D-printed hollow microneedle arrays. Images of sheared-cylinder microneedles printed at (a) 0°, (b) −45°, (c) +45°, and (d) 90° angles with
outlined profiles (insets show the corresponding print setups). SEM images of the (e) conical, (f ) pyramidal, and (g) basic syringe-shaped needle arrays. (h) Average
needle heights for each design (for a subset of 25 microneedles per array). (i) CAD model of the syringe-shaped design and the SEM image of the tip (∼50 μm radius of
curvature). ( j) CAD model of the fine-tip syringe-shaped design (additional features highlighted) and the SEM image of the tip (∼25 μm radius of curvature). (k) SEM
image of the fine-tip microneedle array. (l) Average microneedle heights across three separate fine-tip microneedle arrays (for a subset of 25 microneedles per array).
Error bars indicate ±standard deviation.
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height characterization procedure for three separately printed
fine-tip microneedle arrays and found average heights of 710 μm,
705 μm, and 710 μm [Fig. 2(l)], demonstrating a high degree of
uniformity across multiple arrays.
Penetration characterization of microneedle designs
The performances of the conical, pyramidal, and fine-tip
syringe-shaped microneedle designs were evaluated and compared
following a previously reported penetration test protocol.38
Specifically, penetration was tested on 1.1 mm stacks of parafilm
(8 layers), replicating the mechanical properties of skin.39 The
parafilm technique provides a consistent and convenient method of
visually analyzing penetration by overcoming the inconsistent,
elastic nature of skin and its tendency to recover following penetra-
tion. The microneedle arrays were pressed onto the parafilm stacks
with a 500 g weight (5 N, emulating the force applied by an average
patient40) for 1 min. Then, the first two layers of the parafilm stacks
were imaged. To ensure a uniform stress distribution across the
parafilm, we sanded the back of the microneedle array to remove
residual supporting materials. Figure 3(a) shows the imprint left
behind by each microneedle array. The pyramidal microneedles
left marks on the first layer of parafilm but not on the second.
The conical microneedles merely indented the first layer of
parafilm and also did not affect the second layer. The syringe-
shaped microneedles successfully penetrated the first layer of
parafilm and left behind clear imprints on the second layer,
amounting to penetration depths of at least 130 μm (1 parafilm
layer thickness).
Based on this penetration study, it can be concluded that the
devised syringe-shaped microneedle design maximizes depth and
ease of penetration compared to other designs and is capable of
comfortably piercing through the human stratum corneum
(topmost layer of skin, 10–20 μm thickness41) without excess force.
To further validate the penetration of our syringe-shaped micro-
needle array, we conducted ex vivo porcine skin penetration tests.
FIG. 3. 3D-printed microneedle mechanical characterization: penetration and failure. (a) Penetration test of the pyramidal, conical, and fine-tip syringe-shaped microneedle
arrays across two layers of the parafilm with 5 N of applied force. (b) Mechanical simulation of the fine-tip syringe-shaped microneedle, visualizing the occurrence of
maximal stress at the tip. (c) SEM image of a microneedle before and after penetration testing (demonstrating no tip failure). (d) Axial force vs displacement curve for a
3 × 3 array of syringe-shaped microneedles. The failure point and penetration force are noted. The inset image illustrates the compression test setup.
Biomicrofluidics ARTICLE scitation.org/journal/bmf
Biomicrofluidics 13, 064125 (2019); doi: 10.1063/1.5127778 13, 064125-6
© Author(s) 2019
The microneedle arrays were inserted into neonatal porcine skin
and removed after 1 min, and then the skin surface was stained
with trypan blue (which specifically stains the perforated stratum
corneum sites42) for 5 min. The corresponding images of the pene-
tration area with and without staining are shown in Figs. S2(a) and
S2(b) in the supplementary material. Trypan blue staining
confirmed the penetration of the stratum corneum, evident from
the appearance of blue dots in the skin. Although a few dots are
missing at their respective penetration sites, this can be explained
by the innate inconsistencies of skin and the subsequent limitations
of the trypan blue staining method.42
Syringe-shaped microneedle mechanical
characterization
We simulated the stress distribution experienced by the
fine-tip syringe-shaped interface to identify the location of the
maximum stress (corresponding to microneedle’s primary point of
failure). Figure 3(b) presents a finite element analysis (FEA)
mechanical simulation of the syringe-shaped microneedle (with
conditions matching the conducted penetration test), demonstrat-
ing the concentration of the incurred stress at the tip of the micro-
needle. SEM images of a microneedle pre- and postpenetration
[Fig. 3(c)] confirm that the microneedle tips do not fail or exhibit
noticeable deformation after penetration. Additionally, to assess the
mechanical strength of the 3D-printed microneedles, failure tests
were conducted on five devices (3 × 3 syringe-shaped microneedle
arrays). Following previously reported microneedle compression
tests, a uniaxial load was applied directly onto the microneedle
tips.38 Compression tests [Fig. 3(d)] reveal that failure strength was
∼1.5 N/needle, well above the ∼0.05 N/needle (derived from the
force exerted by the 500 g weight onto 100 needles) penetration
force, thus validating our microneedle’s suitability for on-body
applications.
To further evaluate the mechanical robustness of our micro-
needles and to determine whether they would fracture and leave
behind fragments in the skin during/after application, we coated
the microneedles with fluorescent dye (0.5% wt/vol rhodamine B
for 1 h) and inserted them into porcine skin, then applied a ∼5 N
shear force to induce fracture. Fig. S3(a) in the supplementary
material shows a fluorescent confocal scanning laser microscope
(CLSM) image of the penetration area after the microneedles were
removed, revealing mild staining on the skin surface but no indica-
tion of microneedle fragments. As a positive control, we deliber-
ately fabricated fragile microneedles (an array of 100 needles, each
700 μm tall and 200 μm wide) and repeated the same fracture test.
Fig. S3(b) in the supplementary material shows a CLSM image of
the fragile-microneedle penetration sites, containing spots with
greater fluorescence intensity than the control study, indicating
broken microneedle fragments at these locations. SEM images of
the fragile-microneedles before and after shearing [Figs. S4(a) and
S4(b) in the supplementary material] illustrate that they primarily
exhibit ductile failure and generally remain intact after drastic
plastic deformation. Collectively, these results demonstrate that
the devised syringe-shaped microneedle array possesses high
mechanical stability and do not leave splinters in the skin
during/after application.
Microfluidic modules and mixing
The printed microneedle arrays can be seamlessly integrated
with microfluidic modules by leveraging the one-step fabrication
capability of our approach. To demonstrate the versatility of the
printing scheme in rendering complex architectures, we present
a custom microfluidic module design [shown in Fig. 4(a)],
which can be exploited to perform hydrodynamic mixing. This
design includes three separate inlet microfluidic channels that
converge into a single 3D spiral chamber, where the injected
fluids are hydrodynamically mixed with desired ratios (by mod-
ulating the injected flow rates) and emerge homogenized at the
outlet. The 3D spiral chamber implements a longer overall
length than an equivalent 2D rendition (assuming the same
device length), which is advantageous in facilitating longer paths
for diffusive mixing and promoting a homogenized distribution
at the outlet.
We demonstrated multifluid mixing, using the devised 3D
spiral chamber, through flow rate modulation tests. Three dye-
water solutions were injected through the channels (red-dyed, clear
water, and blue-dyed solutions) at different flow rates, and their
mixing profiles were analyzed. Here, the flow rate ratios are listed
in the following order of solutions: red-dyed, clear water, and blue-
dyed (Q1:Q2:Q3). Figure 4(c) shows the inlet junction when the
flow rates of each inlet were equal to 100 μl/min (Q1:Q2:Q3= 1:1:1,
serving as a baseline for comparison with the other flow rates). At
this flow rate, the onset of mixing and subsequent fully homoge-
nized mixing were observed at the upstream [Fig. 4(c)] and down-
stream [Fig. 4(h)], respectively. When two of the three inlets were
reduced to 10 μl/min, the upstream flow profiles were shifted in
favor of the stream with the higher flow rate [Figs. 4(d)–4(f)]. As a
result, the fluid with a higher flow rate dominated the downstream
solution color [Figs. 4(h)–4( j)].
This effect can be leveraged to tune the outlet solution com-
position (simply by modulating the injected flow rate at each
inlet). To demonstrate this capability, we replaced the original
solutions with fluorescent dyes (rhodamine B, fluorescein isothio-
cyanate, and methylene blue). As illustrated in Fig. 4(b), the
fluorescent dye solutions were directly extracted from the device
outlet after mixing and analyzed using a microplate reader.
Figures 4(k)–4(n) present the fluorescence intensities of each sol-
ution (normalized against the maximum intensity of the corre-
sponding dye measured across all the flow rates, for ease of
comparison). Microplate readings confirm that the concentrations
of the mixtures follow the same trend as that of the input flow
rates (i.e., the higher the relative dye solution flow rate,
the higher the concentration of the dye at the outlet). Overall,
the characterization results demonstrate that by modulating the
injected flow rates at the inlet, we can tune the composition of
the delivered fluid and achieve homogenized mixing of multiple
reagents at the outlet.
Ex vivo transdermal drug delivery
Utilizing the ability of our 3D-printing approach to render
microneedle and microfluidic features simultaneously, we
3D-printed the hydrodynamic mixing microfluidic module and the
fine-tip syringe-shaped microneedle array as a single device to
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FIG. 4. Mixing characterization of the 3D-printed microfluidic architecture. (a) Photograph of the SLA-printed microfluidic mixing architecture with CAD model in the inset.
(b) Schematic of the solution concentration quantification method. (c)–( f ) Microscopic images of the 3D spiral chamber’s inlet junction under various flow rate ratios of
red-dyed, clear, and blue-dyed solutions (Q1:Q2:Q3). (g)–( j) Microscopic images of the 3D spiral chamber’s outlet under the corresponding flow rate ratios. (k)–(n)
Normalized fluorescence (FL) intensities of rhodamine B (RB), fluorescein isothiocyanate (FITC), and methylene blue (MB) present in the solutions obtained from the
outlet. Error bars indicate ±standard deviation (n = 3).
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demonstrate in-situ drug modulation/delivery. In order to assess
the efficacy of our device, we injected rhodamine B, fluorescein iso-
thiocyanate, and methylene blue through the device and into
porcine skin as model-drug molecules. These fluorochromes were
selected because of their similar molecular weights, comparable
diffusion profiles, and distinct excitation and emission peaks.43–45
To quantify drug delivery/modulation, we followed previously
reported CLSM and image analysis techniques,46–48 and analyzed
the penetration depth and relative amounts of the injected fluores-
cent particles.
Figure 5(a) shows the CLSM experimental setup. The device
was placed on a piece of porcine skin (2 × 2 cm) and a 500 g weight
atop the device. Then, the same inlet flow rate ratios from the pre-
vious mixing experiment were applied, while lowering the actual
injected flow rates by a factor of 10 to minimize leakage. The
device was then removed from the porcine skin, and CLSM was
performed on the microneedle penetration sites. CLSM images
were taken at various skin depths, using wavelength-specific excita-
tion lasers and emission filters to examine the fluorescence of
each fluorochrome (shown in Figs. S5–S8 in the supplementary
material). Figures 5(b)–5(d) illustrate the normalized fluorescence
intensities of the CLSM images at each flow rate ratio (see
Materials and Methods). The insets of Figs. 5(b)–5(d) present the
cumulative fluorescence intensities of the characterized skin depths
(0–400 μm), as a quantitative proxy measure of the total amount of
each dye transdermally delivered. The raw measured fluorescence
intensities of the 1:1:1 baseline flow is shown in Fig. S9 in the
supplementary material. Compared to the 1:1:1 baseline, fluoro-
chromes with higher flow rates exhibited a significantly increased
fluorescence signal (indicating larger transdermally delivered
amounts), which is aligned with the trend observed in the previous
microfluidic characterization. Additionally, the imaged fluorescence
intensities were highest between 100 and 200 μm, indicating that
the fluorochromes were able to reach penetration depths of at least
100 μm, which is aligned with penetration test results from Fig. 3.
In summary, the ex vivo skin characterization results demonstrate
the device’s potential for on-demand and programmable drug
delivery via modulation of the input fluid solutions’ flow rates.
FIG. 5. Ex vivo transdermal model-drug delivery characterization. (a) The schematic diagram of the experimental setup and the CLSM imaging area. Normalized fluores-
cence (FL) intensities from CLSM imaging of rhodamine B (RB), fluorescein isothiocyanate (FITC), and methylene blue (MB) on porcine skin at (b) 0.1:0.1:1, (c) 0.1:1:0.1,
and (d) 1:0.1:0.1 flow rate ratios across 0–400 μm skin depths (normalized with respect to the 1:1:1 baseline). Insets show the total fluorescence intensity of each dye (the
area under the normalized intensity vs the skin depth curve) for the corresponding injection conditions.
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CONCLUSIONS
Here, we presented an SLA-based 3D-printing scheme to render
integrated microfluidic-enabled hollow microneedle devices for trans-
dermal drug delivery. Scanning electron microscopy showed the accu-
racy, consistency, and repeatability of the 3D-printing scheme across
multiple hollow microneedle array designs. Penetration and fracture
tests confirmed the microneedles’ mechanical robustness for practical
application. An example microfluidic-enabled microneedle device
was printed with our devised scheme that facilitates homogeneous
mixing of multiple fluids under different flow rates, followed by
transdermal delivery of the mixed solution. Comparisons of various
flow rate ratios with colored dye solutions showed tunable control
over the relative concentrations of solutes delivered. Ex vivo confocal
laser scanning microscopy of three fluorochrome model-drug solu-
tions on porcine skin further validated the platform’s ability for trans-
dermal drug modulation and delivery.
This 3D-printed device is particularly applicable to preclinical
investigations centered on combinational drug therapy, where the
in-situ combination of multiple drugs and the tuning of their phys-
icochemical properties lead to more effective outcomes than single
or premixed agents alone. For example, the controlled multifluidic
synthesis of nanoparticles can tune the release mechanisms of
various drugs for wound healing applications.49 By leveraging the
low-cost and multiscale/high speed printing of SLA, while pushing
its resolution limits to render fine hollow microneedle features, the
devised fabrication scheme presents new device design possibilities
and degrees of freedom for transdermal drug delivery.
SUPPLEMENTARY MATERIAL
See the supplementary material for details on print orienta-
tion characterization (Fig. S1), penetration tests on porcine skin
(Fig. S2), microneedle mechanical stability and failure (Figs. S3
and S4), model-drug delivery characterization under various flow
rates (Figs. S5–S9), false printing effects (Fig. S10), and the hole
formation rate (Fig. S11).
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